Parabolic Drugs Ltd
Parabolic Drugs engages in the manufacture and contract manufacture of active pharmaceutical ingredients (API) and API intermediates.
- Market Cap ₹ 34.0 Cr.
- Current Price ₹ 5.50
- High / Low ₹ /
- Stock P/E
- Book Value ₹ -150
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Company has low interest coverage ratio.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
395 | 513 | 617 | 919 | 763 | 438 | 231 | 75 | 73 | 71 | 18 | 0 | 0 | |
335 | 430 | 515 | 762 | 836 | 519 | 310 | 381 | 118 | 87 | 33 | 6 | 5 | |
Operating Profit | 60 | 83 | 102 | 157 | -73 | -82 | -78 | -306 | -46 | -15 | -15 | -6 | -5 |
OPM % | 15% | 16% | 17% | 17% | -10% | -19% | -34% | -410% | -62% | -22% | -82% | ||
2 | 5 | 15 | 4 | 6 | 13 | 1 | 0 | 4 | 4 | -1 | 0 | 0 | |
Interest | 28 | 38 | 41 | 64 | 73 | 83 | 99 | 108 | 10 | 9 | 3 | 1 | 1 |
Depreciation | 4 | 6 | 8 | 31 | 55 | 68 | 73 | 67 | 53 | 35 | 23 | 22 | 21 |
Profit before tax | 30 | 44 | 69 | 66 | -195 | -220 | -249 | -481 | -105 | -55 | -42 | -29 | -26 |
Tax % | 20% | 22% | 23% | 23% | -28% | -40% | 52% | 1% | 3% | 3% | -1% | 0% | |
24 | 34 | 53 | 51 | -140 | -132 | -379 | -485 | -108 | -57 | -41 | -29 | -26 | |
EPS in Rs | 8.54 | 8.27 | -22.58 | -21.28 | -61.29 | -78.39 | -17.46 | -9.21 | -6.69 | -4.63 | -4.21 | ||
Dividend Payout % | 0% | 0% | 6% | 3% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -100% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 14% |
3 Years: | 20% |
TTM: | 12% |
Stock Price CAGR | |
---|---|
10 Years: | -7% |
5 Years: | 56% |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Sep 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 11 | 37 | 62 | 62 | 62 | 62 | 62 | 62 | 62 | 62 | 62 | 62 | 62 |
Reserves | 89 | 121 | 317 | 367 | 239 | 121 | -258 | -743 | -851 | -908 | -949 | -977 | -990 |
289 | 421 | 474 | 555 | 777 | 842 | 957 | 972 | 979 | 984 | 985 | 157 | 158 | |
121 | 111 | 214 | 331 | 161 | 202 | 189 | 287 | 303 | 281 | 275 | 1,108 | 1,109 | |
Total Liabilities | 510 | 690 | 1,067 | 1,314 | 1,239 | 1,227 | 950 | 577 | 493 | 419 | 372 | 349 | 339 |
97 | 130 | 163 | 188 | 334 | 331 | 395 | 371 | 349 | 326 | 298 | 278 | 267 | |
CWIP | 19 | 41 | 112 | 187 | 72 | 81 | 7 | 7 | 7 | 7 | 7 | 7 | 7 |
Investments | 2 | 2 | 6 | 4 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
392 | 517 | 786 | 936 | 827 | 809 | 542 | 193 | 132 | 80 | 62 | 59 | 59 | |
Total Assets | 510 | 690 | 1,067 | 1,314 | 1,239 | 1,227 | 950 | 577 | 493 | 419 | 372 | 349 | 339 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-40 | -31 | 3 | 207 | -111 | 28 | -4 | 90 | 2 | 3 | |||
-56 | -87 | -180 | -205 | -108 | -30 | -16 | 1 | 0 | 1 | |||
103 | 122 | 186 | 7 | 197 | -4 | 17 | -93 | -2 | -4 | |||
Net Cash Flow | 6 | 4 | 8 | 9 | -23 | -6 | -3 | -2 | -0 | 0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 135 | 137 | 163 | 88 | 66 | 124 | 155 | 342 | 335 | 148 | 562 | |
Inventory Days | 234 | 239 | 276 | 237 | 167 | 363 | 450 | 45 | 61 | 91 | 12 | |
Days Payable | 123 | 82 | 137 | 149 | 59 | 187 | 146 | 104 | 420 | 465 | 1,325 | |
Cash Conversion Cycle | 246 | 294 | 302 | 176 | 174 | 301 | 460 | 283 | -24 | -226 | -751 | |
Working Capital Days | 225 | 255 | 263 | 154 | 206 | 301 | 454 | -535 | -766 | -864 | -3,645 | |
ROCE % | 19% | 17% | 15% | 14% | -12% | -13% | -17% | -71% | -39% | -28% | -31% |
Documents
Announcements
- Outcome Of Board Meeting Held On 11.02.2021 And Intimation Of Financial Results For The Quarter And Nine Months Ended 31.122020 11 Feb 2021
-
Corporate Insolvency Resolution Process (CIRP)-Public Announcement
8 Feb 2021 - In reference to the captioned matter and as per the Resolution Plan approved by Hon'ble National Company Law Tribunal, Chandigarh Bench ('NCLT') in terms of …
- Board Meeting Intimation for Un-Audited Quarterly Financial Results For The Quarter And Nine Months Ended On 31St December, 2020 5 Feb 2021
- Fixation Of 'Record Date' For Suspension Of Trading Of Units/Scrip 25 Jan 2021
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
22 Jan 2021 - Depositories and Participants) Regulations, 2018, please find enclosed herewith the certificate received from Link Intime India Private Limited (herein called as 'RTA') for the Quarter …